 |
市場調查報告書
商品編碼
1913935
細胞療法製造市場規模、佔有率和成長分析（按治療方法、細胞來源、營運規模和地區分類）—2026-2033年產業預測Cell Therapy Manufacturing Market Size, Share, and Growth Analysis, By Therapy Type (T Cell Therapies, Stem Cell Therapies), By Cell Source (Autologous, Allogeneic), By Scale of Operation, By Region -Industry Forecast 2026-2033. |
||||||
預計到 2024 年，全球細胞療法製造市場規模將達到 56.8 億美元，到 2025 年將達到 68.4 億美元，到 2033 年將達到 302.1 億美元，預測期（2026-2033 年）的複合年成長率為 20.4%。
細胞療法需求的不斷成長推動了生產製造領域的創新，重點在於自動化、封閉式生物反應器和先進分析技術，以確保產品的一致性和符合監管要求。商業化生產設施的激增反映了這一趨勢，尤其是在關鍵地區，成長尤為顯著。然而，這種快速擴張也引發了人們對資料隱私、監管合規和品管的嚴重擔憂。報告指出，針對細胞療法公司的網路攻擊頻傳，凸顯了採取強而有力的資料保護措施的必要性。此外，生產流程的日益複雜化導致召回和監管警告的增加，凸顯了在產業快速發展過程中，如何持續維護品質和病人安全所面臨的挑戰。
全球細胞療法生產市場按療法類型、細胞來源、業務規模和地區進行細分。依療法類型分類，可分為T細胞療法、幹細胞療法和樹突細胞療法。依細胞來源分類，可分為自體細胞、異體細胞及未明確來源細胞。依業務規模分類，可分為臨床規模和商業規模。按地區分類，分析涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。
全球細胞療法製造市場促進因素
癌症和自體免疫免疫疾病等慢性病發病率的上升顯著推動了細胞療法生產的需求。每年數百萬新增癌症病例促使人們需要CAR-T細胞療法和幹細胞療法等先進療法。這種不斷成長的需求刺激了對先進生產技術和可擴展製造解決方案的投資，使生物技術公司能夠有效地滿足尚未滿足的醫療需求。因此，市場准入正在顯著改善，尤其是在腫瘤學和再生醫學領域，因為各公司都在尋求創新並適應不斷變化的醫療保健格局。
全球細胞療法製造市場面臨的限制因素
全球細胞療法生產市場面臨許多限制因素，主要源自於生產流程的複雜性和高成本。諸如CAR-T療法等個人化療法需要精密的設備和專業的醫護人員，這往往導致每位患者的治療費用非常高。高成本限制了患者的可及性，尤其是在低收入社區，並阻礙了擴充性。此外，細胞品質不穩定和生產週期長等挑戰也增加了生產的複雜性。這些因素共同阻礙了市場的建立和發展，為擴大治療覆蓋率和提高治療效率設置了難以克服的障礙。
全球細胞療法製造市場趨勢
在全球細胞治療生產市場，採用封閉式系統和自動化技術已成為一個顯著趨勢，顯著提高了營運效率和擴充性。透過利用機器人系統和生物反應器，製造商減少了人為干預，降低了污染風險，並確保符合良好生產規範 (GMP)。一次性生物反應器的應用增強了無菌性，最大限度地降低了成本，並加快了生產週期。這對於同種異體移植療法尤其有利，使其能夠滿足北美和亞太等關鍵地區（尤其是在腫瘤學和再生醫學領域）日益成長的細胞治療需求。
目錄
介紹
- 調查目標
- 調查範圍
- 定義
調查方法
- 資訊收集
- 二手資料和一手資料方法
- 市場規模預測
- 市場假設與限制
執行摘要
- 全球市場展望
- 供需趨勢分析
- 細分市場機會分析
市場動態與展望
- 市場規模
- 市場動態
- 促進因素和機遇
- 限制與挑戰
- 波特分析
關鍵市場考察
- 關鍵成功因素
- 競爭程度
- 關鍵投資機會
- 市場生態系統
- 市場吸引力指數（2025）
- PESTEL 分析
- 總體經濟指標
- 價值鏈分析
- 定價分析
- 技術分析
- 案例研究
- 顧客購買行為分析
全球細胞療法製造市場規模（依治療方法分類）及複合年成長率（2026-2033 年）
- T細胞療法
- 幹細胞療法
- 樹突細胞療法
全球細胞療法製造市場規模（按細胞來源和複合年成長率分類）（2026-2033 年）
- 自體
- 同種異體移植
- 未指定
全球細胞療法製造市場規模（按企業規模和複合年成長率分類）（2026-2033 年）
- 臨床
- 商業的
全球細胞療法製造市場規模及複合年成長率（2026-2033）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
- 拉丁美洲
- 巴西
- 其他拉丁美洲地區
- 中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區
競爭資訊
- 前五大公司對比
- 主要企業的市場定位（2025 年）
- 主要市場參與者所採取的策略
- 近期市場趨勢
- 公司市佔率分析（2025 年）
- 主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- AGC Biologics
- Charles River Laboratories
- FUJIFILM Cellular Dynamics
- Thermo Fisher Scientific
- WuXi AppTec
- Lonza
- Catalent
- BioNTech
- Cell and Gene Therapy Catapult
- Cell Therapies Pty Ltd
- Merck KGaA
- Takara Bio
- Bristol Myers Squibb
- Novartis
結論與建議
Global Cell Therapy Manufacturing Market size was valued at USD 5.68 Billion in 2024 and is poised to grow from USD 6.84 Billion in 2025 to USD 30.21 Billion by 2033, growing at a CAGR of 20.4% in the forecast period (2026-2033).
The escalating demand for cell therapy is driving innovation in manufacturing techniques, with a focus on automation, closed-system bioreactors, and advanced analytics to ensure product consistency and regulatory adherence. The proliferation of commercial manufacturing facilities reflects this trend, with significant growth observed in key regions. However, this rapid expansion has raised critical concerns regarding data privacy, regulatory compliance, and quality control. Reports indicate a notable incidence of cyberattacks targeting cell therapy firms, emphasizing the need for robust data protection measures. Additionally, the complexity of manufacturing processes has resulted in an uptick in recalls and regulatory warnings, highlighting the ongoing challenges in maintaining quality and patient safety amid the industry's rapid evolution.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cell Therapy Manufacturing Market Segments Analysis
The global cell therapy manufacturing marketis segmented into therapy type, cell source, scale of operation, and region. By therapy type, the market is classified into T cell therapies, stem cell therapies, and dendritic cell therapies. Depending on the cell source, it is divided into autologous, allogeneic, and unspecified. According to scale of operation , the market is categorized into clinical and commercial. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Driver of the Global Cell Therapy Manufacturing Market
The rising incidence of chronic conditions such as cancer and autoimmune disorders significantly fuels the demand for cell therapy manufacturing. With millions of new cancer diagnoses annually, the need for advanced treatments like CAR-T and stem cell therapies is on the rise. This growing demand propels investment in cutting-edge production technologies and scalable manufacturing solutions, allowing biotech firms to address unmet medical needs effectively. Consequently, there is a notable enhancement in market accessibility, particularly within the fields of oncology and regenerative medicine, as companies strive to innovate and meet the evolving healthcare landscape.
Restraints in the Global Cell Therapy Manufacturing Market
The Global Cell Therapy Manufacturing market faces significant constraints due to the intricate and costly nature of the manufacturing process. Customized treatments, like CAR-T therapy, require advanced facilities and expert personnel, often exceeding substantial financial outlays per patient. Such high costs restrict access, especially in low-income regions, and hinder the potential for scalability. Moreover, challenges such as variability in cell quality and lengthy production timelines further contribute to the complexity of manufacturing. These factors collectively impede the establishment and growth of the market, creating obstacles that are difficult to navigate in expanding access and efficiency.
Market Trends of the Global Cell Therapy Manufacturing Market
The Global Cell Therapy Manufacturing market is witnessing a significant trend towards the implementation of closed system and automation technologies, enhancing operational efficiency and scalability. By leveraging robotic systems and bioreactors, manufacturers are reducing human interaction, thereby lowering the risk of contamination and ensuring compliance with Good Manufacturing Practices (GMP). The adoption of single-use bioreactors enhances sterility while minimizing costs and expediting production timelines. This is particularly advantageous for allogeneic therapies, allowing manufacturers to meet the rising demand for cell therapies across key regions such as North America and the Asia-Pacific, particularly in oncology and regenerative medicine sectors.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Technology Analysis
- Case Studies
- Customer Buying Behavior Analysis
Global Cell Therapy Manufacturing Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- T cell therapies
- Stem cell therapies
- Dendritic cell therapies
Global Cell Therapy Manufacturing Market Size by Cell Source & CAGR (2026-2033)
- Market Overview
- Autologous
- Allogeneic
- Unspecified
Global Cell Therapy Manufacturing Market Size by Scale of Operation & CAGR (2026-2033)
- Market Overview
- Clinical
- Commercial
Global Cell Therapy Manufacturing Market Size & CAGR (2026-2033)
- North America (Therapy Type, Cell Source, Scale of Operation)
- US
- Canada
- Europe (Therapy Type, Cell Source, Scale of Operation)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapy Type, Cell Source, Scale of Operation)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapy Type, Cell Source, Scale of Operation)
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapy Type, Cell Source, Scale of Operation)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- FUJIFILM Cellular Dynamics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioNTech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cell and Gene Therapy Catapult
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cell Therapies Pty Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takara Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
細胞療法製造市場－全球產業規模、佔有率、趨勢、競爭格局、機會及預測（依治療方法、細胞來源、營運規模、供應來源、應用、最終用戶、地區和競爭格局分類），2021-2031年
全球細胞治療製造市場按治療類型、技術類型、製造目的、應用和地區分類